Interaction between baseline HBV loads and the prognosis of patients with HCC who receive anti-PD-1 in combination with anantiangiogenic therapy and are simultaneously given TAF prophylaxis
Xiaoyun Hu1*, Rong Li1*, Qi Li1, Mengya Zang1, Guosheng Yuan1#, Jinzhang Chen1#
Short Running title: Interaction between HBV and anti-PD-1 plus antiangiogenic therapy
Keywords : Hepatocellular carcinoma (HCC); hepatitis B virus (HBV); programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1); reactivation; tenofovir alafenamide fumarate (TAF)
1Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China
#Correspondence authors: Guosheng Yuan, PhD; Jinzhang Chen, MD. Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, 1,838 North Guangzhou Ave, Guangzhou, Guangdong 510515, China. Email: guoshengyuan1991@163.com; chenjinzhang@smu.edu.cn.